BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Telix Doses First Patient in ZOLAR Phase 1 Trial for Advanced Soft Tissue Sarcoma

Telix Pharmaceuticals Limited announces that a first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx (89Zr-olaratumab) in patients wit...

April 02, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Luye Pharma’s Twice-Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Luye Pharma Group announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japa...

April 01, 2025 | News

Merck Secures Global Rights to Abbisko’s Pimicotinib with $85M Option Exercise

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), w...

April 01, 2025 | News

Sichuan Kelun-Biotech Gets Green Light for First Radionuclide-Drug Conjugate Clinical Trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the invest...

March 26, 2025 | News

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

China’s AIM Vaccine Gets FDA Nod for mRNA Shingles Vaccine Trial

AIM Vaccine Co., developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). As o...

March 25, 2025 | News

CStone Submits EMA Application to Expand Sugemalimab Use in Stage III Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submiss...

March 25, 2025 | News

Shanghai ArkBio Completes Phase III Trial of AK0901 for Pediatric ADHD in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of a...

March 25, 2025 | News

Ractigen Reports Promising Phase I Data for First-in-Class saRNA Therapy RAG-01 in Bladder Cancer

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, announced the presentation of...

March 25, 2025 | News

Sungen Biomedical Secures FDA Fast Track Designation for AMI Drug Candidate SGC001

Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Designa...

March 25, 2025 | News

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Stay Connected